Grading prostate cancer

Dernière révision médicale :

Grading describes how the cancer cells look compared to normal, healthy cells. Knowing the grade gives your healthcare team an idea of how quickly the cancer may be growing and how likely it is to spread. This helps them plan your treatment. The grade can also help the healthcare team predict future outcomes (your prognosis) and how the cancer might respond to treatment.

Gleason classification system

The Gleason classification system is most often used to grade prostate cancer. It is used for adenocarcinoma, which is the most common type of prostate cancer. The Gleason classification system looks at the differentiation of cancer cells and the pattern (arrangement) of the cancer cells in the prostate. Differentiation describes how different the cancer cells are.

Gleason patterns and grade

To find out the grade of prostate cancer, the pathologist looks at tissue samples from the prostate under a microscope.

There are 5 patterns of prostate cancer cells based on their differentiation. The lower the pattern number, the more cancer cells look, act and are arranged like normal cells. The pathologist will give a grade for each pattern of prostate cancer cells found in the biopsy. The grade of the cancer corresponds to the pattern number. Gleason patterns 1 and 2 look a lot like normal cells. Gleason pattern 5 looks very abnormal compared to normal cells. Gleason patterns 3 and 4 are somewhere in between. Most prostate cancers have a Gleason pattern of 3, 4 or 5.

Calculating the Gleason score

If the pathologist sees only 2 patterns of cancer cells, they will add the grades for each pattern together to get the total Gleason score. For example, if the pathologist gives the cancer cells in the most common pattern a grade of 3 and the cancer cells in the second most common pattern a grade of 4, the total Gleason score is 7. This is often written on the pathology report as 3 + 4 = 7 out of 10.

If there is a third pattern in the biopsy samples, the grade of the most common pattern of cancer cells is added to the pattern with the highest grade. This may be the second most common pattern or the least most common pattern. For example, if the pathologist gives the cancer cells in the most common pattern a grade of 3, the cancer cells in the second most common pattern a grade of 4, and another pattern of cancer cells a grade of 5, the total Gleason score is 8.

Grade group

To make the Gleason score easier to understand, doctors developed the Grade Group system. This gives a single score from 1 to 5 based on increasing Gleason scores. For example, Grade Group 1 corresponds to a Gleason score of 6 and Grade Group 5 corresponds to a Gleason score of 9 or 10.

Gleason score descriptions

The Gleason score and Grade Group are described in the following table.

Group grade

Gleason score

Description

1

6 or less The cancer is likely to grow and spread very slowly (called well differentiated or low grade).

2

3 + 4 = 7

The cancer is likely to grow and spread slowly (called moderately differentiated or intermediate grade).

3

4 + 3 = 7

The cancer is likely to grow and spread slowly (called moderately differentiated or intermediate grade). Grade Group 3 is more likely to grow and spread than Grade Group 2.

4

8

The cancer is likely to grow and spread quickly (called poorly differentiated or high grade).

5

9 or 10

The cancer is likely to grow and spread quickly (called poorly differentiated or high grade). Grade Group 5 is likely to grow and spread more quickly than Grade Group 4.

Révision par les experts et références

  • Peter Chung, MBChB, FRCPC
  • Krista Noonan, MD, FRCPC
  • American Cancer Society. Prostate Cancer Early Detection, Diagnosis, and Staging. 2019: https://www.cancer.org/.
  • American Cancer Society. Prostate Cancer. Atlanta, GA: American Cancer Society; 2015: https://www.cancer.org/.
  • Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. American Journal of Surgical Pathology. 2016:
  • Garnick MB (ed.). Harvard Medical School 2015 Annual Report on Prostate Diseases. 2015:
  • PDQ® Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ®)–Health Professional Version. Bethesda, MD: National Cancer Institute; 2020: https://www.cancer.gov/.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 3.2020). 2020:

Votre source de confiance pour des informations fiables sur le cancer

Le soutien des lecteurs comme vous nous permet de continuer à fournir des informations de la plus haute qualité sur plus de 100 types de cancer.

Nous sommes là pour vous garantir un accès facile à des informations fiables sur le cancer, ainsi qu’aux millions de personnes qui visitent ce site Web chaque année. Mais nous ne pouvons pas y arriver seuls.

Chaque don nous permet d’offrir des informations fiables sur le cancer et finance des services de soutien empreints de compassion et des projets de recherche prometteurs. Faites un don dès maintenant, car chaque dollar compte. Nous vous remercions.

Non-responsabilité médicale

L'information fournie par la Société canadienne du cancer ne saurait remplacer le lien qui vous unit à votre médecin. Nos renseignements sont d’ordre général; avant de prendre toute décision de nature médicale ou si vous avez des questions concernant votre état de santé personnel, assurez-vous de parler à un professionnel de la santé qualifié.

Nous faisons le maximum pour que les renseignements que nous diffusons soient toujours exacts et fiables, mais nous ne pouvons garantir leur exhaustivité, pas plus que l’absence totale d’erreur.

La Société canadienne du cancer n’assume aucune responsabilité quant à la qualité des renseignements ou des services offerts par d'autres organismes mentionnés sur cancer.ca, pas plus qu’elle ne cautionne un service, un produit, un traitement ou une thérapie en particulier. 


1-888-939-3333 | cancer.ca | © 2026 Canadian Cancer Society